Cardiac xenotransplantation: Clinical experience and future direction

被引：13

作者：

Adams, DH ^{[1
]}

Chen, RH ^{[1
]}

Kadner, A ^{[1
]}

机构：

[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiac Surg, Boston, MA 02115 USA

来源：

ANNALS OF THORACIC SURGERY | 2000年 / 70卷 / 01期

关键词：

D O I：

10.1016/S0003-4975(00)01281-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The shortage of human organs has focused research on finding an animal source of replacement organs. The immunological barriers to xenotransplantation are now more clearly defined, allowing retrospective interpretation of past clinical experience in humans. Due to physiological compatibilities as well as ethical and infectious considerations, pigs have now emerged as the most likely source of future xenografts. The introduction of transgenic pigs expressing human complement regulatory proteins and new immunosuppressive regimens have shown early promise in the laboratory, although further advancements are needed to advance to clinical trials. Additional clarification of infectious risks and patient strategies are remaining obstacles to application in the clinical arena. (Ann Thorac Surg 2000;70:320-6) (C) 2000 by The Society of Thoracic Surgeons.

引用

页码：320 / 326

页数：7

共 66 条

[1]

BACH FH, 1995, TRANSPLANT P, V27, P77

[2] Delayed xenograft rejection [J].

Bach, FH ;

Winkler, H ;

Ferran, C ;

Hancock, WW ;

Robson, SC .

IMMUNOLOGY TODAY, 1996, 17 (08) :379-384

[3] BABOON-TO-HUMAN CARDIAC XENOTRANSPLANTATION IN A NEONATE [J].

BAILEY, LL ;

NEHLSENCANNARELLA, SL ;

CONCEPCION, W ;

JOLLEY, WB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 254 (23) :3321-3329

[4]

BARNARD CN, 1977, S AFR MED J, V52, P1035

[5] ACTIVATION OF INTRAGRAFT ENDOTHELIAL AND MONONUCLEAR-CELLS DURING DISCORDANT XENOGRAFT REJECTION [J].

BLAKELY, ML ;

VANDERWERF, WJ ;

BERNDT, MC ;

DALMASSO, AP ;

BACH, FH ;

HANCOCK, WW .

TRANSPLANTATION, 1994, 58 (10) :1059-1066

[6] RELATIVE ROLES OF DECAY-ACCELERATING FACTOR, MEMBRANE COFACTOR PROTEIN, AND CD59 IN THE PROTECTION OF HUMAN ENDOTHELIAL-CELLS AGAINST COMPLEMENT-MEDIATED LYSIS [J].

BROOIMANS, RA ;

VANWIERINGEN, PAM ;

VANES, LA ;

DAHA, MR .

EUROPEAN JOURNAL OF IMMUNOLOGY, 1992, 22 (12) :3135-3140

[7] Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage [J].

Byrne, G ;

McCurry, KR ;

Martin, MJ ;

McClellan, SM ;

Platt, JL ;

Logan, JS .

TRANSPLANTATION, 1997, 63 (01) :149-155

[8] PROTECTION OF XENOGENEIC CARDIAC ENDOTHELIUM FROM HUMAN-COMPLEMENT BY EXPRESSION OF CD59 OR DAF IN TRANSGENIC MICE [J].

BYRNE, GW ;

MCCURRY, KR ;

KAGAN, D ;

QUINN, C ;

MARTIN, MJ ;

PLATT, JL ;

LOGAN, JS .

TRANSPLANTATION, 1995, 60 (10) :1149-1156

[9]

Cairns T, 1995, TRANSPLANTATION, V60, P1202

[10]

Caplan AL, 1998, DIALYSIS TRANSPLANT, V27, P618

← 1 2 3 4 5 6 7 →